Compare iShares MSCI South Korea ETF (EWY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares MSCI South Korea ETF is far larger — about 234× Inovio Pharmaceuticals Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWY | INO | |
|---|---|---|
Market Cap | $26.25B | $112.19M |
Volume | 19,056,075 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $2.60 |
52-Week Low | $80.72 | $0.66 |
Typical Hold Time | 47 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $176.33, down 4.02% amid bearish technical signals, with moving averages indicating selling pressure. The ETF faces headwinds from rising US yields and oil prices impacting South Korean tech stocks, though RSI levels suggest potential oversold conditions. Recent volatility reflects sensitivity to AI sector dynamics and global macroeconomic factors.
Outlook remains cautious due to concentrated exposure to semiconductor giants Samsung and SK Hynix, creating dependency on memory cycle strength. Investment opportunity exists if AI demand sustains earnings growth, but risks include Fed policy impacts and geopolitical tensions. Governance reforms and deleveraging provide fundamental support amid market turbulence.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
